[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@JD4for4 Jordan Alexander
Jordan Alexander posts on X about $qure, $nktr, $lly, nktr the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +29%
- X Year XXXXXXX +106%
Mentions: X #
- X Week X -XX%
- X Month XX -X%
- X Months XXX no change
- X Year XXX +196%
Followers: XXXXX #
- X Week XXXXX +0.41%
- X Month XXXXX +2.10%
- X Months XXXXX +8.40%
- X Year XXXXX +16%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence countries XXXXX% stocks XXXX% finance XXXX% travel destinations XXXX%
Social topic influence $qure #26, $nktr #3, $lly #6, nktr #2, $nvct 1.64%, edinburgh 1.64%, university of 1.64%, $25b 1.64%, 100k 1.64%, breakthrough #395
Top accounts mentioned or mentioned by @dalvinvarnado @nichola68773113 @biotechgurubest @veracityroad @seedy19tron @amaymd @pawcio2009 @monacobiotech @lucy3370 @wz2013 @maxpowerngs @biotech2050 @sangamotx @fda @seckennedy @andersresearch @mellowrklion @mchilberg @ong_0x @mellowrk_lion
Top assets mentioned uniQure N.V. (QURE) Eli Lilly and Company (LLY)
Top Social Posts #
Top posts by engagements in the last XX hours
"uniQures AMT-130 Gene Therapy Breakthrough Moment for Huntingtons Disease Unprecedented XX% Reduction in Huntingtons Disease Progression $QURE Key Insight: AMT-130 demonstrates the first credible evidence that a gene therapy can meaningfully alter the natural course of Huntingtons disease. Given the strength and durability of the clinical signal FDA approval appears highly likely positioning QURE as an exceptionally attractive takeover candidate. Breakthrough in Huntingtons Disease uniQures AMT-130 may mark the most important breakthrough in Huntingtons disease the first therapy to show it"
X Link @JD4for4 2025-10-08T02:43Z 8291 followers, 3232 engagements
"you could be right but could also have morphed into bd. the $NKTR settlement is already sunk cost to $LLY & nobody has deeper pockets. One thing I know is that it is very unlikely gov't shutdown because: Settlement talks are privileged and confidential under federal and most state evidence rules. Publicly stating the parties are in settlement talks could affect leverage & investor perception. Courts prefer to encourage candid negotiation without press or third-party scrutiny. So instead of naming settlement judges often cite procedural reasons judicial economy case management calendar"
X Link @JD4for4 2025-10-16T20:26Z 8291 followers, XXX engagements
"$NVCT NXP900 #ANE2025 abstract title 10/23: A099 NXP900 a novel YES1/SRC kinase inhibitor currently in clinical development potently inhibits tumor growth in FAT1 mutated xenograft models. Asier Unciti-Broceta. University of Edinburgh Edinburgh UK. The new FAT1-mutant PDX work extends the preclinical models into human-derived systemsreinforcing the translational bridge that defines NXP900s biomarker-guided clinical strategy. ➡ As the first human PDX study of NXP900 it builds on prior TNBC in-vivo data and substantiates the logic behind FAT1 loss as a key biomarker for patient enrichment in"
X Link @JD4for4 2025-10-13T18:11Z 8285 followers, 1774 engagements
"Goldman analyst be needing 👓 $2.5B peak sales is 1k of 40k symptomatic of 100k HD patients $QURE early sales likely $2.5B & rise from there especially as many more get diagnosed once theres a breakthrough therapy like AMT-130. 3-5x mult gets you closer to $20B $XXX ps"
X Link @JD4for4 2025-10-11T16:51Z 8284 followers, 8008 engagements
"Maybe some are finally noticing that the $QURE AMT-130 efficacy delta vs control is widening at X yr endpoint"
X Link @JD4for4 2025-10-07T19:57Z 8285 followers, 9973 engagements
"Tabrizi calls $QURE AMT-130 spectacular & Wild breathtaking"
X Link @JD4for4 2025-10-12T14:04Z 8286 followers, 5186 engagements
"Another explanation for the $LLY $NKTR pretrial delay return to rezpeg collaboration settlement good reason for the trial delay without any explanation and likely re-rate NKTRs valuation upward several-fold over @seedy19tron litigation model Thoughts X. From conflict to collaboration $LLY and $NKTR already built rezpeg together it was a Lilly-led program from their 2017 partnership. The fallout was about how Lilly ran the trials and Nektars claim that Lillys study design and communication effectively undermined the drugs perceived value. Now with Nektars independent Phase 2b"
X Link @JD4for4 2025-10-16T12:28Z 8291 followers, 7126 engagements